Kronos Bio, Inc. financial data

Symbol
KRON on Nasdaq
Industry
Pharmaceutical Preparations
Location
1300 S. El Camino Real, Suite 400, San Mateo, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 779 % -28.3%
Debt-to-equity 33.6 % +42.9%
Return On Equity -68.8 % -34.9%
Return On Assets -51.5 % -24.7%
Operating Margin -1.32K % +68.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.3M shares +3.39%
Common Stock, Shares, Outstanding 60.3M shares +3.7%
Entity Public Float 48.3M USD -76.4%
Common Stock, Value, Issued 60K USD +3.45%
Weighted Average Number of Shares Outstanding, Basic 60.1M shares +4.71%
Weighted Average Number of Shares Outstanding, Diluted 60.1M shares +4.71%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.41M USD +173%
Research and Development Expense 73.9M USD -15.1%
General and Administrative Expense 35.3M USD -14.1%
Operating Income (Loss) -111M USD +13.1%
Nonoperating Income (Expense) 8.33M USD +5.98%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -103M USD +14.3%
Earnings Per Share, Basic -1.74 USD/shares +17.5%
Earnings Per Share, Diluted -1.74 USD/shares +17.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 70.2M USD +58.1%
Cash, Cash Equivalents, and Short-term Investments 248M USD -27%
Assets, Current 141M USD -37%
Property, Plant and Equipment, Net 7.66M USD -35.2%
Operating Lease, Right-of-Use Asset 12.8M USD -39.6%
Other Assets, Noncurrent 577K USD -50.6%
Assets 164M USD -37%
Accounts Payable, Current 990K USD -63%
Employee-related Liabilities, Current 1.6M USD -35.5%
Accrued Liabilities, Current 4.45M USD -35.8%
Contract with Customer, Liability, Current 7.53M USD -14.7%
Liabilities, Current 16.6M USD -24.6%
Contract with Customer, Liability, Noncurrent 974K USD -88%
Operating Lease, Liability, Noncurrent 23.5M USD -13.3%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 41.1M USD -28.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -36K USD +92.3%
Retained Earnings (Accumulated Deficit) -555M USD -22.7%
Stockholders' Equity Attributable to Parent 123M USD -39.4%
Liabilities and Equity 164M USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.9M USD -302%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 5.77M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 60.3M shares +3.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.1M USD -47.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 72.2M USD +55.6%
Deferred Tax Assets, Valuation Allowance 123M USD +22.2%
Deferred Tax Assets, Gross 127M USD +18%
Operating Lease, Liability 27.1M USD -10.1%
Depreciation 1.84M USD -33.3%
Payments to Acquire Property, Plant, and Equipment 7K USD -94.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -102M USD +14.5%
Lessee, Operating Lease, Liability, to be Paid 35.1M USD -14.7%
Property, Plant and Equipment, Gross 15.8M USD -14.2%
Operating Lease, Liability, Current 3.62M USD +19.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.39M USD -8.92%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.91M USD +2.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.94M USD -27.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.86M USD -10%
Deferred Tax Assets, Operating Loss Carryforwards 68.3M USD +16.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.37M USD +43.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.01M USD
Operating Lease, Payments 5.7M USD -3.39%
Additional Paid in Capital 678M USD +3.39%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.28M USD +4.02%
Deferred Tax Assets, Net of Valuation Allowance 3.56M USD -46.1%
Share-based Payment Arrangement, Expense 21.4M USD -25.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%